Immune Cell Subsets in SLE Patients Treated with Telitacicept

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT06677801
Phase
PHASE4
Status
Active Not Recruiting

Conditions

  • Systemic Lupus Erythematosus (SLE)

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Telitacicept 160mg — BIOLOGICAL
    Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.

Study Details

This study is a single-center cohort study. Patients with SLE who met the inclusion criteria were treated with tetanercept 160 mg once a week for a total of 24 weeks, and the clinical and laboratory indicators were collected before treatment, at the 4th week, at the 12th week, and at the 24th week, and blood samples were collected for the detection of immune cell subsets.

Key Dates

Start date
Oct 11, 2024
Status verified
Nov 2024
Primary completion
Oct 31, 2026
Completion
Oct 31, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Active Comparator: Participant Group
    SLE patients treated with Telitacicept

Primary Outcome Measure

Changes of immune cell subsets after treatment [ Time Frame: 24 weeks ]

Related Studies